全体要約
2023年の濾胞性リンパ腫の治療市場は1673.9百万米ドルと評価され、2030年には2163.7百万米ドルに達する見込みで、年平均成長率は3.7%です。
市場の成長には、製品の差別化やコスト削減、サプライチェーンの最適化が重要です。市場参加者は研究開発に投資し、戦略的パートナーシップを結ぶ必要があります。
濾胞性リンパ腫は白血球に影響を与える癌で、主に抗CD20モノクローナル抗体や化学療法薬、キナーゼ阻害剤が治療に用いられます。市場は、アメリカ、アジア太平洋、ヨーロッパ、中東・アフリカの地域に分かれ、病院やクリニックでの利用が見込まれています。
関連する質問
1673.9百万米ドル（2023年）
3.7%（2023年から2030年）
Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Celgene Corporation, Celldex Therapeutics, Inc., Celltrion, Inc., Cellular Biomedicine Group, Inc., Coherus BioSciences, Inc., CTI BioPharma Corp., Curis, Inc., Dynavax Technologies Corporation, Eisai, EpiZyme, Inc., F. Hoffmann-La Roche Ltd., Genentech, Inc., Gilead Sciences, Inc., GlaxoSmithKline Plc, Hutchison MediPharma Limited, Immune Design Corp., ImmunoGen, Inc.
製品の差別化, コスト削減, サプライチェーンの最適化
概要
この研究報告は、世界の濾胞性リンパ腫治療市場の成長可能性を強調しています。濾胞性リンパ腫治療は、将来の市場で安定した成長を示すと予想されています。しかし、製品の差別化、コスト削減、サプライチェーンの最適化は、濾胞性リンパ腫治療の広範な採用にとって重要です。市場のプレーヤーは、研究開発に投資し、戦略的パートナーシップを構築し、進化する消費者の好みに合わせて提供を調整する必要があります。これにより、濾胞性リンパ腫治療市場がもたらす巨大な機会を活かすことができます。
濾胞性リンパ腫は、リンパ球と呼ばれる白血球に影響を与える癌です。リンパ腫には、影響を与える白血球の種類に基づいてホジキンリンパ腫と非ホジキンリンパ腫の2種類があります。濾胞性リンパ腫は非ホジキンリンパ腫です。濾胞性リンパ腫の薬剤には、Anti-CD20 mAbs、化学療法剤、キナーゼ阻害剤などがあります。
2022年の世界の製薬市場規模は1475億USDであり、今後6年間にわたり年平均成長率（CAGR）は5%と推定されています。製薬市場には、化学薬品と生物学的製剤が含まれます。生物学的製剤は2022年に381億USDに達すると予想されています。一方、化学薬品市場は2018年の1005億USDから2022年には1094億USDに増加すると見込まれています。製薬市場の要因には、医療需要の増加、技術革新、慢性疾患の増加、製薬製造分野の発展のための民間・政府からの資金増加、及び薬剤の研究開発活動の増加があります。しかし、業界は、厳しい規制、研究開発の高コスト、特許の期限切れといった課題にも直面しています。企業は、市場で競争力を保ち、製品が必要な患者に届くように、これらの課題に対して絶えず革新を続け、適応する必要があります。また、COVID-19パンデミックは、ワクチン開発とサプライチェーン管理の重要性を浮き彫りにし、公衆衛生の新たなニーズに迅速に対応する必要性をさらに強調しました。
主な特徴：
濾胞性リンパ腫治療市場に関する報告書は、さまざまな側面を反映しており、業界に対する貴重な洞察を提供。
市場規模と成長：この調査報告書は、濾胞性リンパ腫治療市場の現在の規模と成長の概要を提供します。歴史的データ、種類別の市場セグメンテーション（例：化学療法、放射線療法）、および地域別の内訳が含まれる場合があります。
市場の推進要因と課題：報告書では、フォリキュラーリンパ腫治療市場の成長を促進する要因を特定し分析することができます。これには、政府の規制、環境への懸念、技術の進歩、消費者の嗜好の変化などが含まれます。また、インフラの制限、レンジアキシエティ、高い初期コストなど、業界が直面している課題も強調することができます。
競争環境：この調査報告書は、濾胞性リンパ腫治療市場における競争環境の分析を提供します。主要なプレーヤーのプロフィール、市場シェア、戦略、および製品提供が含まれています。また、登場するプレーヤーと彼らの市場への潜在的な影響についても強調される可能性があります。
技術革新：この研究報告書では、濾胞性リンパ腫治療産業における最新の技術革新について詳しく調査することができます。これには、濾胞性リンパ腫治療技術の進展、濾胞性リンパ腫治療の新規参入者、濾胞性リンパ腫治療の新たな投資、そして濾胞性リンパ腫治療の未来を形作るその他の革新が含まれます。
下流の購買者の好み：この報告書は、濾胞性リンパ腫治療市場における顧客の購買行動や採用傾向についての洞察を提供することができます。顧客の購入決定に影響を与える要因や濾胞性リンパ腫治療製品に対する好みも含まれています。
政府の政策とインセンティブ：調査報告書は、濾胞性リンパ腫治療市場に対する政府の政策やインセンティブの影響を分析しています。これには、規制枠組み、助成金、税優遇措置、そして濾胞性リンパ腫治療市場の促進を目的としたその他の措置の評価が含まれる可能性があります。報告書はまた、市場成長を促進する上でこれらの政策の効果を評価しています。
環境影響と持続可能性：この研究報告書は、濾胞性リンパ腫治療市場の環境影響と持続可能性の側面を評価しています。
市場予測と今後の見通し：実施された分析に基づき、研究報告書は濾胞性リンパ腫治療産業の市場予測と見通しを提供します。これには、市場規模、成長率、地域動向、技術の進展や政策の発展に関する予測が含まれます。
推奨事項と機会：この報告書は、業界の利害関係者、政策立案者、および投資家への推奨事項で締めくくられています。市場のプレーヤーが新たなトレンドを活用し、課題を克服し、濾胞性リンパ腫治療市場の成長と発展に貢献するための潜在的な機会を強調しています。
市場セグメンテーション：
濾胞性リンパ腫治療市場は、タイプ別およびアプリケーション別に分かれています。2019年から2030年の期間において、セグメント間の成長は、タイプ別およびアプリケーション別の消費価値について正確な計算と予測を提供します。
タイプ別のセグメンテーション
化学療法
放射線療法
モノクローナル抗体
幹細胞移植
用途別のセグメンテーション
病院
クリニック
その他
この報告書は地域別にも市場を分割しています。
アメリカ大陸
アメリカ合衆国
カナダ
メキシコ
ブラジル
アジア太平洋地域
中国
日本
韓国
東南アジア
インド
オーストラリア
ヨーロッパ
ドイツ
フランス
イギリス
イタリア
ロシア
中東およびアフリカ
エジプト
南アフリカ
イスラエル
トルコ
GCC諸国
以下の企業は、主要な専門家から収集した情報と、企業のカバレッジ、製品ポートフォリオ、市場浸透率を分析した結果に基づいて選定されています。
ベーリンガーインゲルハイム社
ブリストル・マイヤーズ スクイブ社
セルジーン社
セルデックス・セラピューティクス社
セルトリオン株式会社
セルラーバイオメディシングループ株式会社
コヒルス・バイオサイエンシズ社
CTIバイオファーマ社
キュリス社
ダイナバックス・テクノロジーズ社
エーザイ
エピザイム社
F. ホフマン・ラ・ロシュ株式会社
ジェネンテック社
ギリアド・サイエンシズ社
グラクソ・スミスクライン株式会社
ハチソンメディファーマリミテッド
イミューンデザイン社
イムノジェン株式会社
※以下の目次にて、具体的なレポートの構成をご覧頂けます。ご購入、無料サンプルご請求、その他お問い合わせは、ページ上のボタンよりお進みください。
目次
1 調査範囲
1.1 市場イントロダクション
1.2 対象年
1.3 調査目的
1.4 市場調査手法
1.5 調査プロセスとデータソース
1.6 経済指標
1.7 通貨
1.8 市場予測における留意事項
2 エグゼクティブサマリー
2.1 世界市場概要
2.1.1 グローバルの濾胞性リンパ腫の治療市場規模、（2019年～2030年）
2.1.2 濾胞性リンパ腫の治療市場規模、CAGR（地域別）（2019年 vs 2023年 vs 2030年）
2.2 濾胞性リンパ腫の治療セグメント、タイプ別
2.2.1 化学療法
2.2.2 放射線治療
2.2.3 モノクローナル抗体
2.2.4 ステムセル移植
2.3 濾胞性リンパ腫の治療市場規模：タイプ別
2.3.1 濾胞性リンパ腫の治療市場規模、CAGR（タイプ別）（2019年 vs 2023年 vs 2030年）
2.3.2 グローバルの濾胞性リンパ腫の治療市場規模、市場シェア（タイプ別）（2019年～2024年）
2.4 濾胞性リンパ腫の治療セグメント、用途別
2.4.1 病院
2.4.2 クリニック
2.4.3 その他
2.5 濾胞性リンパ腫の治療市場規模：用途別
2.5.1 濾胞性リンパ腫の治療市場規模、CAGR（用途別）（2019年 vs 2023年 vs 2030年）
2.5.2 グローバルの濾胞性リンパ腫の治療市場規模、市場シェア（用途別）（2019年～2024年）
3 濾胞性リンパ腫の治療市場規模：プレイヤー別
3.1 濾胞性リンパ腫の治療市場規模、市場シェア（プレイヤー別）
3.1.1 グローバルにおける濾胞性リンパ腫の治療市場の収益規模、プレイヤー別（2019年～2024年）
3.1.2 グローバルにおける濾胞性リンパ腫の治療市場の収益シェア、プレイヤー別（2019年～2024年）
3.2 グローバルの濾胞性リンパ腫の治療市場キープレイヤー拠点および提供製品
3.3 市場集中度分析
3.3.1 競合情勢分析
3.3.2 集中度レシオ（CR3、CR5、CR10）（2022年～2024年）
3.4 新製品・潜在的参入
3.5 M&A、拡大
4 濾胞性リンパ腫の治療、地域別
4.1 濾胞性リンパ腫の治療市場規模（地域別）（2019年～2024年）
4.2 アメリカズにおける濾胞性リンパ腫の治療市場規模成長（2019年〜2024年）
4.3 APACにおける濾胞性リンパ腫の治療市場規模成長（2019年〜2024年）
4.4 ヨーロッパにおける濾胞性リンパ腫の治療市場規模成長（2019年〜2024年）
4.5 中東・アフリカにおける濾胞性リンパ腫の治療市場規模成長（2019年〜2024年）
5 アメリカズ
5.1 アメリカズにおける濾胞性リンパ腫の治療市場規模、国別（2019年〜2024年）
5.2 アメリカズにおける濾胞性リンパ腫の治療市場規模、タイプ別（2019年〜2024年）
5.3 アメリカズにおける濾胞性リンパ腫の治療市場規模、用途別（2019年〜2024年）
5.4 米国
5.5 カナダ
5.6 メキシコ
5.7 ブラジル
6 APAC
6.1 APACにおける濾胞性リンパ腫の治療市場規模、地域別（2019年〜2024年）
6.2 APACにおける濾胞性リンパ腫の治療市場規模、タイプ別（2019年〜2024年）
6.3 APACにおける濾胞性リンパ腫の治療市場規模、用途別（2019年〜2024年）
6.4 中国
6.5 日本
6.6 韓国
6.7 東南アジア
6.8 インド
6.9 オーストラリア
7 ヨーロッパ
7.1 ヨーロッパの濾胞性リンパ腫の治療 国別（2019年～2024年）
7.2 ヨーロッパにおける濾胞性リンパ腫の治療市場規模、タイプ別（2019年〜2024年）
7.3 ヨーロッパにおける濾胞性リンパ腫の治療市場規模、用途別（2019年〜2024年）
7.4 ドイツ
7.5 フランス
7.6 英国
7.7 イタリア
7.8 ロシア
8 中東・アフリカ
8.1 中東・アフリカの濾胞性リンパ腫の治療 地域別（2019年～2024年）
8.2 中東・アフリカにおける濾胞性リンパ腫の治療市場規模、タイプ別（2019年〜2024年）
8.3 中東・アフリカにおける濾胞性リンパ腫の治療市場規模、用途別（2019年〜2024年）
8.4 エジプト
8.5 南アフリカ
8.6 イスラエル
8.7 トルコ
8.8 GCC地域
9 市場ドライバー・課題・トレンド
9.1 市場ドライバー・成長機会
9.2 市場課題・リスク
9.3 業界トレンド
10 グローバルの濾胞性リンパ腫の治療市場、市場予測
10.1 グローバルの濾胞性リンパ腫の治療、市場予測（地域別）（2025年～2030年）
10.1.1 グローバルの濾胞性リンパ腫の治療、市場予測（地域別）（2025年～2030年）
10.1.2 アメリカズの濾胞性リンパ腫の治療、市場予測
10.1.3 APACの濾胞性リンパ腫の治療、市場予測
10.1.4 ヨーロッパの濾胞性リンパ腫の治療、市場予測
10.1.5 中東・アフリカの濾胞性リンパ腫の治療、市場予測
10.2 アメリカズの濾胞性リンパ腫の治療、市場予測（国別）（2025年～2030年）
10.3 APACの濾胞性リンパ腫の治療、市場予測（地域別）（2025年～2030年）
10.4 ヨーロッパの濾胞性リンパ腫の治療、市場予測（国別）（2025年～2030年）
10.5 中東・アフリカの濾胞性リンパ腫の治療、市場予測（地域別）（2025年～2030年）
10.6 グローバルの濾胞性リンパ腫の治療、市場予測（タイプ別）（2025年～2030年）
10.7 グローバルの濾胞性リンパ腫の治療、市場予測（用途別）（2025年～2030年）
11 キープレイヤー分析
11.1 Boehringer Ingelheim GmbH
11.1.1 Boehringer Ingelheim GmbH：企業情報
11.1.2 Boehringer Ingelheim GmbH：濾胞性リンパ腫の治療分野の提供製品
11.1.3 Boehringer Ingelheim GmbH：濾胞性リンパ腫の治療収益・グロスマージンおよび市場シェア（2019年～2024年）
11.1.4 Boehringer Ingelheim GmbH：主要事業概要
11.1.5 Boehringer Ingelheim GmbH：直近の展開
11.2 Bristol-Myers Squibb Company
11.2.1 Bristol-Myers Squibb Company：企業情報
11.2.2 Bristol-Myers Squibb Company：濾胞性リンパ腫の治療分野の提供製品
11.2.3 Bristol-Myers Squibb Company：濾胞性リンパ腫の治療収益・グロスマージンおよび市場シェア（2019年～2024年）
11.2.4 Bristol-Myers Squibb Company：主要事業概要
11.2.5 Bristol-Myers Squibb Company：直近の展開
11.3 Celgene Corporation
11.3.1 Celgene Corporation：企業情報
11.3.2 Celgene Corporation：濾胞性リンパ腫の治療分野の提供製品
11.3.3 Celgene Corporation：濾胞性リンパ腫の治療収益・グロスマージンおよび市場シェア（2019年～2024年）
11.3.4 Celgene Corporation：主要事業概要
11.3.5 Celgene Corporation：直近の展開
11.4 Celldex Therapeutics, Inc
11.5 Celltrion, Inc
11.6 Cellular Biomedicine Group, Inc
11.7 Coherus BioSciences, Inc
11.8 CTI BioPharma Corp
11.9 Curis, Inc
11.10 Dynavax Technologies Corporation
11.10.1 Dynavax Technologies Corporation：企業情報
11.10.2 Dynavax Technologies Corporation：濾胞性リンパ腫の治療分野の提供製品
11.10.3 Dynavax Technologies Corporation：濾胞性リンパ腫の治療収益・グロスマージンおよび市場シェア（2019年～2024年）
11.10.4 Dynavax Technologies Corporation：主要事業概要
11.10.5 Dynavax Technologies Corporation：直近の展開
11.11 Eisai
11.11.1 Eisai：企業情報
11.11.2 Eisai：濾胞性リンパ腫の治療分野の提供製品
11.11.3 Eisai：濾胞性リンパ腫の治療収益・グロスマージンおよび市場シェア（2019年～2024年）
11.11.4 Eisai：主要事業概要
11.11.5 Eisai：直近の展開
11.12 EpiZyme, Inc
11.13 F\. Hoffmann-La Roche Ltd
11.14 Genentech, Inc
11.15 Gilead Sciences, Inc
11.16 GlaxoSmithKline Plc
11.16.1 GlaxoSmithKline Plc：企業情報
11.16.2 GlaxoSmithKline Plc：濾胞性リンパ腫の治療分野の提供製品
11.16.3 GlaxoSmithKline Plc：濾胞性リンパ腫の治療収益・グロスマージンおよび市場シェア（2019年～2024年）
11.16.4 GlaxoSmithKline Plc：主要事業概要
11.16.5 GlaxoSmithKline Plc：直近の展開
11.17 Hutchison MediPharma Limited
11.17.1 Hutchison MediPharma Limited：企業情報
11.17.2 Hutchison MediPharma Limited：濾胞性リンパ腫の治療分野の提供製品
11.17.3 Hutchison MediPharma Limited：濾胞性リンパ腫の治療収益・グロスマージンおよび市場シェア（2019年～2024年）
11.17.4 Hutchison MediPharma Limited：主要事業概要
11.17.5 Hutchison MediPharma Limited：直近の展開
11.18 Immune Design Corp
11.19 ImmunoGen, Inc
12 調査の結果・結論
※英文のレポートについての日本語表記のタイトルや紹介文などは、すべて生成AIや自動翻訳ソフトを使用して提供しております。それらはお客様の便宜のために提供するものであり、当社はその内容について責任を負いかねますので、何卒ご了承ください。適宜英語の原文をご参照ください。
“All Japanese titles, abstracts, and other descriptions of English-language reports were created using generative AI and/or machine translation. These are provided for your convenience only and may contain errors and inaccuracies. Please be sure to refer to the original English-language text. We disclaim all liability in relation to your reliance on such AI-generated and/or machine-translated content.”
Description
The research report highlights the growth potential of the global Follicular Lymphoma Treatment market. Follicular Lymphoma Treatment are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Follicular Lymphoma Treatment. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Follicular Lymphoma Treatment market.
Follicular lymphoma is a cancer that affects white blood cells called lymphocytes. There are two types of lymphomas: Hodgkin's and non-Hodgkin's, based on the kind of white blood cell they affect. Follicular lymphoma is a non-Hodgkin's lymphoma.Drugs for Follicular lymphoma are Anti-CD20 mAbs, Chemotherapy Agents, Kinase Inhibitor, etc.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Key Features:
The report on Follicular Lymphoma Treatment market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Follicular Lymphoma Treatment market. It may include historical data, market segmentation by Type (e.g., Chemotherapy, Radiotherapy), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Follicular Lymphoma Treatment market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Follicular Lymphoma Treatment market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Follicular Lymphoma Treatment industry. This include advancements in Follicular Lymphoma Treatment technology, Follicular Lymphoma Treatment new entrants, Follicular Lymphoma Treatment new investment, and other innovations that are shaping the future of Follicular Lymphoma Treatment.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Follicular Lymphoma Treatment market. It includes factors influencing customer ' purchasing decisions, preferences for Follicular Lymphoma Treatment product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Follicular Lymphoma Treatment market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Follicular Lymphoma Treatment market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Follicular Lymphoma Treatment market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Follicular Lymphoma Treatment industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Follicular Lymphoma Treatment market.
Market Segmentation:
Follicular Lymphoma Treatment market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Segmentation by type
Chemotherapy
Radiotherapy
Monoclonal Antibodies
Stem Cell Transplantation
Segmentation by application
Hospital
Clinic
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Celgene Corporation
Celldex Therapeutics, Inc.
Celltrion, Inc.
Cellular Biomedicine Group, Inc.
Coherus BioSciences, Inc.
CTI BioPharma Corp.
Curis, Inc.
Dynavax Technologies Corporation
Eisai
EpiZyme, Inc.
F. Hoffmann-La Roche Ltd.
Genentech, Inc.
Gilead Sciences, Inc.
GlaxoSmithKline Plc
Hutchison MediPharma Limited
Immune Design Corp.
ImmunoGen, Inc.
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Follicular Lymphoma Treatment Market Size 2019-2030
2.1.2 Follicular Lymphoma Treatment Market Size CAGR by Region 2019 VS 2023 VS 2030
2.2 Follicular Lymphoma Treatment Segment by Type
2.2.1 Chemotherapy
2.2.2 Radiotherapy
2.2.3 Monoclonal Antibodies
2.2.4 Stem Cell Transplantation
2.3 Follicular Lymphoma Treatment Market Size by Type
2.3.1 Follicular Lymphoma Treatment Market Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Follicular Lymphoma Treatment Market Size Market Share by Type (2019-2024)
2.4 Follicular Lymphoma Treatment Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.4.3 Others
2.5 Follicular Lymphoma Treatment Market Size by Application
2.5.1 Follicular Lymphoma Treatment Market Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Follicular Lymphoma Treatment Market Size Market Share by Application (2019-2024)
3 Follicular Lymphoma Treatment Market Size by Player
3.1 Follicular Lymphoma Treatment Market Size Market Share by Players
3.1.1 Global Follicular Lymphoma Treatment Revenue by Players (2019-2024)
3.1.2 Global Follicular Lymphoma Treatment Revenue Market Share by Players (2019-2024)
3.2 Global Follicular Lymphoma Treatment Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Follicular Lymphoma Treatment by Regions
4.1 Follicular Lymphoma Treatment Market Size by Regions (2019-2024)
4.2 Americas Follicular Lymphoma Treatment Market Size Growth (2019-2024)
4.3 APAC Follicular Lymphoma Treatment Market Size Growth (2019-2024)
4.4 Europe Follicular Lymphoma Treatment Market Size Growth (2019-2024)
4.5 Middle East & Africa Follicular Lymphoma Treatment Market Size Growth (2019-2024)
5 Americas
5.1 Americas Follicular Lymphoma Treatment Market Size by Country (2019-2024)
5.2 Americas Follicular Lymphoma Treatment Market Size by Type (2019-2024)
5.3 Americas Follicular Lymphoma Treatment Market Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Follicular Lymphoma Treatment Market Size by Region (2019-2024)
6.2 APAC Follicular Lymphoma Treatment Market Size by Type (2019-2024)
6.3 APAC Follicular Lymphoma Treatment Market Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Follicular Lymphoma Treatment by Country (2019-2024)
7.2 Europe Follicular Lymphoma Treatment Market Size by Type (2019-2024)
7.3 Europe Follicular Lymphoma Treatment Market Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Follicular Lymphoma Treatment by Region (2019-2024)
8.2 Middle East & Africa Follicular Lymphoma Treatment Market Size by Type (2019-2024)
8.3 Middle East & Africa Follicular Lymphoma Treatment Market Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Follicular Lymphoma Treatment Market Forecast
10.1 Global Follicular Lymphoma Treatment Forecast by Regions (2025-2030)
10.1.1 Global Follicular Lymphoma Treatment Forecast by Regions (2025-2030)
10.1.2 Americas Follicular Lymphoma Treatment Forecast
10.1.3 APAC Follicular Lymphoma Treatment Forecast
10.1.4 Europe Follicular Lymphoma Treatment Forecast
10.1.5 Middle East & Africa Follicular Lymphoma Treatment Forecast
10.2 Americas Follicular Lymphoma Treatment Forecast by Country (2025-2030)
10.2.1 United States Follicular Lymphoma Treatment Market Forecast
10.2.2 Canada Follicular Lymphoma Treatment Market Forecast
10.2.3 Mexico Follicular Lymphoma Treatment Market Forecast
10.2.4 Brazil Follicular Lymphoma Treatment Market Forecast
10.3 APAC Follicular Lymphoma Treatment Forecast by Region (2025-2030)
10.3.1 China Follicular Lymphoma Treatment Market Forecast
10.3.2 Japan Follicular Lymphoma Treatment Market Forecast
10.3.3 Korea Follicular Lymphoma Treatment Market Forecast
10.3.4 Southeast Asia Follicular Lymphoma Treatment Market Forecast
10.3.5 India Follicular Lymphoma Treatment Market Forecast
10.3.6 Australia Follicular Lymphoma Treatment Market Forecast
10.4 Europe Follicular Lymphoma Treatment Forecast by Country (2025-2030)
10.4.1 Germany Follicular Lymphoma Treatment Market Forecast
10.4.2 France Follicular Lymphoma Treatment Market Forecast
10.4.3 UK Follicular Lymphoma Treatment Market Forecast
10.4.4 Italy Follicular Lymphoma Treatment Market Forecast
10.4.5 Russia Follicular Lymphoma Treatment Market Forecast
10.5 Middle East & Africa Follicular Lymphoma Treatment Forecast by Region (2025-2030)
10.5.1 Egypt Follicular Lymphoma Treatment Market Forecast
10.5.2 South Africa Follicular Lymphoma Treatment Market Forecast
10.5.3 Israel Follicular Lymphoma Treatment Market Forecast
10.5.4 Turkey Follicular Lymphoma Treatment Market Forecast
10.5.5 GCC Countries Follicular Lymphoma Treatment Market Forecast
10.6 Global Follicular Lymphoma Treatment Forecast by Type (2025-2030)
10.7 Global Follicular Lymphoma Treatment Forecast by Application (2025-2030)
11 Key Players Analysis
11.1 Boehringer Ingelheim GmbH
11.1.1 Boehringer Ingelheim GmbH Company Information
11.1.2 Boehringer Ingelheim GmbH Follicular Lymphoma Treatment Product Offered
11.1.3 Boehringer Ingelheim GmbH Follicular Lymphoma Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.1.4 Boehringer Ingelheim GmbH Main Business Overview
11.1.5 Boehringer Ingelheim GmbH Latest Developments
11.2 Bristol-Myers Squibb Company
11.2.1 Bristol-Myers Squibb Company Company Information
11.2.2 Bristol-Myers Squibb Company Follicular Lymphoma Treatment Product Offered
11.2.3 Bristol-Myers Squibb Company Follicular Lymphoma Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.2.4 Bristol-Myers Squibb Company Main Business Overview
11.2.5 Bristol-Myers Squibb Company Latest Developments
11.3 Celgene Corporation
11.3.1 Celgene Corporation Company Information
11.3.2 Celgene Corporation Follicular Lymphoma Treatment Product Offered
11.3.3 Celgene Corporation Follicular Lymphoma Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.3.4 Celgene Corporation Main Business Overview
11.3.5 Celgene Corporation Latest Developments
11.4 Celldex Therapeutics, Inc.
11.4.1 Celldex Therapeutics, Inc. Company Information
11.4.2 Celldex Therapeutics, Inc. Follicular Lymphoma Treatment Product Offered
11.4.3 Celldex Therapeutics, Inc. Follicular Lymphoma Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.4.4 Celldex Therapeutics, Inc. Main Business Overview
11.4.5 Celldex Therapeutics, Inc. Latest Developments
11.5 Celltrion, Inc.
11.5.1 Celltrion, Inc. Company Information
11.5.2 Celltrion, Inc. Follicular Lymphoma Treatment Product Offered
11.5.3 Celltrion, Inc. Follicular Lymphoma Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.5.4 Celltrion, Inc. Main Business Overview
11.5.5 Celltrion, Inc. Latest Developments
11.6 Cellular Biomedicine Group, Inc.
11.6.1 Cellular Biomedicine Group, Inc. Company Information
11.6.2 Cellular Biomedicine Group, Inc. Follicular Lymphoma Treatment Product Offered
11.6.3 Cellular Biomedicine Group, Inc. Follicular Lymphoma Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.6.4 Cellular Biomedicine Group, Inc. Main Business Overview
11.6.5 Cellular Biomedicine Group, Inc. Latest Developments
11.7 Coherus BioSciences, Inc.
11.7.1 Coherus BioSciences, Inc. Company Information
11.7.2 Coherus BioSciences, Inc. Follicular Lymphoma Treatment Product Offered
11.7.3 Coherus BioSciences, Inc. Follicular Lymphoma Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.7.4 Coherus BioSciences, Inc. Main Business Overview
11.7.5 Coherus BioSciences, Inc. Latest Developments
11.8 CTI BioPharma Corp.
11.8.1 CTI BioPharma Corp. Company Information
11.8.2 CTI BioPharma Corp. Follicular Lymphoma Treatment Product Offered
11.8.3 CTI BioPharma Corp. Follicular Lymphoma Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.8.4 CTI BioPharma Corp. Main Business Overview
11.8.5 CTI BioPharma Corp. Latest Developments
11.9 Curis, Inc.
11.9.1 Curis, Inc. Company Information
11.9.2 Curis, Inc. Follicular Lymphoma Treatment Product Offered
11.9.3 Curis, Inc. Follicular Lymphoma Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.9.4 Curis, Inc. Main Business Overview
11.9.5 Curis, Inc. Latest Developments
11.10 Dynavax Technologies Corporation
11.10.1 Dynavax Technologies Corporation Company Information
11.10.2 Dynavax Technologies Corporation Follicular Lymphoma Treatment Product Offered
11.10.3 Dynavax Technologies Corporation Follicular Lymphoma Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.10.4 Dynavax Technologies Corporation Main Business Overview
11.10.5 Dynavax Technologies Corporation Latest Developments
11.11 Eisai
11.11.1 Eisai Company Information
11.11.2 Eisai Follicular Lymphoma Treatment Product Offered
11.11.3 Eisai Follicular Lymphoma Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.11.4 Eisai Main Business Overview
11.11.5 Eisai Latest Developments
11.12 EpiZyme, Inc.
11.12.1 EpiZyme, Inc. Company Information
11.12.2 EpiZyme, Inc. Follicular Lymphoma Treatment Product Offered
11.12.3 EpiZyme, Inc. Follicular Lymphoma Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.12.4 EpiZyme, Inc. Main Business Overview
11.12.5 EpiZyme, Inc. Latest Developments
11.13 F. Hoffmann-La Roche Ltd.
11.13.1 F. Hoffmann-La Roche Ltd. Company Information
11.13.2 F. Hoffmann-La Roche Ltd. Follicular Lymphoma Treatment Product Offered
11.13.3 F. Hoffmann-La Roche Ltd. Follicular Lymphoma Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.13.4 F. Hoffmann-La Roche Ltd. Main Business Overview
11.13.5 F. Hoffmann-La Roche Ltd. Latest Developments
11.14 Genentech, Inc.
11.14.1 Genentech, Inc. Company Information
11.14.2 Genentech, Inc. Follicular Lymphoma Treatment Product Offered
11.14.3 Genentech, Inc. Follicular Lymphoma Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.14.4 Genentech, Inc. Main Business Overview
11.14.5 Genentech, Inc. Latest Developments
11.15 Gilead Sciences, Inc.
11.15.1 Gilead Sciences, Inc. Company Information
11.15.2 Gilead Sciences, Inc. Follicular Lymphoma Treatment Product Offered
11.15.3 Gilead Sciences, Inc. Follicular Lymphoma Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.15.4 Gilead Sciences, Inc. Main Business Overview
11.15.5 Gilead Sciences, Inc. Latest Developments
11.16 GlaxoSmithKline Plc
11.16.1 GlaxoSmithKline Plc Company Information
11.16.2 GlaxoSmithKline Plc Follicular Lymphoma Treatment Product Offered
11.16.3 GlaxoSmithKline Plc Follicular Lymphoma Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.16.4 GlaxoSmithKline Plc Main Business Overview
11.16.5 GlaxoSmithKline Plc Latest Developments
11.17 Hutchison MediPharma Limited
11.17.1 Hutchison MediPharma Limited Company Information
11.17.2 Hutchison MediPharma Limited Follicular Lymphoma Treatment Product Offered
11.17.3 Hutchison MediPharma Limited Follicular Lymphoma Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.17.4 Hutchison MediPharma Limited Main Business Overview
11.17.5 Hutchison MediPharma Limited Latest Developments
11.18 Immune Design Corp.
11.18.1 Immune Design Corp. Company Information
11.18.2 Immune Design Corp. Follicular Lymphoma Treatment Product Offered
11.18.3 Immune Design Corp. Follicular Lymphoma Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.18.4 Immune Design Corp. Main Business Overview
11.18.5 Immune Design Corp. Latest Developments
11.19 ImmunoGen, Inc.
11.19.1 ImmunoGen, Inc. Company Information
11.19.2 ImmunoGen, Inc. Follicular Lymphoma Treatment Product Offered
11.19.3 ImmunoGen, Inc. Follicular Lymphoma Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.19.4 ImmunoGen, Inc. Main Business Overview
11.19.5 ImmunoGen, Inc. Latest Developments
12 Research Findings and Conclusion
List of Tables Table 1. Follicular Lymphoma Treatment Market Size CAGR by Region (2019 VS 2023 VS 2030) & ($ Millions) Table 2. Major Players of Chemotherapy Table 3. Major Players of Radiotherapy Table 4. Major Players of Monoclonal Antibodies Table 5. Major Players of Stem Cell Transplantation Table 6. Follicular Lymphoma Treatment Market Size CAGR by Type (2019 VS 2023 VS 2030) & ($ Millions) Table 7. Global Follicular Lymphoma Treatment Market Size by Type (2019-2024) & ($ Millions) Table 8. Global Follicular Lymphoma Treatment Market Size Market Share by Type (2019-2024) Table 9. Follicular Lymphoma Treatment Market Size CAGR by Application (2019 VS 2023 VS 2030) & ($ Millions) Table 10. Global Follicular Lymphoma Treatment Market Size by Application (2019-2024) & ($ Millions) Table 11. Global Follicular Lymphoma Treatment Market Size Market Share by Application (2019-2024) Table 12. Global Follicular Lymphoma Treatment Revenue by Players (2019-2024) & ($ Millions) Table 13. Global Follicular Lymphoma Treatment Revenue Market Share by Player (2019-2024) Table 14. Follicular Lymphoma Treatment Key Players Head office and Products Offered Table 15. Follicular Lymphoma Treatment Concentration Ratio (CR3, CR5 and CR10) & (2022-2024) Table 16. New Products and Potential Entrants Table 17. Mergers & Acquisitions, Expansion Table 18. Global Follicular Lymphoma Treatment Market Size by Regions 2019-2024 & ($ Millions) Table 19. Global Follicular Lymphoma Treatment Market Size Market Share by Regions (2019-2024) Table 20. Global Follicular Lymphoma Treatment Revenue by Country/Region (2019-2024) & ($ millions) Table 21. Global Follicular Lymphoma Treatment Revenue Market Share by Country/Region (2019-2024) Table 22. Americas Follicular Lymphoma Treatment Market Size by Country (2019-2024) & ($ Millions) Table 23. Americas Follicular Lymphoma Treatment Market Size Market Share by Country (2019-2024) Table 24. Americas Follicular Lymphoma Treatment Market Size by Type (2019-2024) & ($ Millions) Table 25. Americas Follicular Lymphoma Treatment Market Size Market Share by Type (2019-2024) Table 26. Americas Follicular Lymphoma Treatment Market Size by Application (2019-2024) & ($ Millions) Table 27. Americas Follicular Lymphoma Treatment Market Size Market Share by Application (2019-2024) Table 28. APAC Follicular Lymphoma Treatment Market Size by Region (2019-2024) & ($ Millions) Table 29. APAC Follicular Lymphoma Treatment Market Size Market Share by Region (2019-2024) Table 30. APAC Follicular Lymphoma Treatment Market Size by Type (2019-2024) & ($ Millions) Table 31. APAC Follicular Lymphoma Treatment Market Size Market Share by Type (2019-2024) Table 32. APAC Follicular Lymphoma Treatment Market Size by Application (2019-2024) & ($ Millions) Table 33. APAC Follicular Lymphoma Treatment Market Size Market Share by Application (2019-2024) Table 34. Europe Follicular Lymphoma Treatment Market Size by Country (2019-2024) & ($ Millions) Table 35. Europe Follicular Lymphoma Treatment Market Size Market Share by Country (2019-2024) Table 36. Europe Follicular Lymphoma Treatment Market Size by Type (2019-2024) & ($ Millions) Table 37. Europe Follicular Lymphoma Treatment Market Size Market Share by Type (2019-2024) Table 38. Europe Follicular Lymphoma Treatment Market Size by Application (2019-2024) & ($ Millions) Table 39. Europe Follicular Lymphoma Treatment Market Size Market Share by Application (2019-2024) Table 40. Middle East & Africa Follicular Lymphoma Treatment Market Size by Region (2019-2024) & ($ Millions) Table 41. Middle East & Africa Follicular Lymphoma Treatment Market Size Market Share by Region (2019-2024) Table 42. Middle East & Africa Follicular Lymphoma Treatment Market Size by Type (2019-2024) & ($ Millions) Table 43. Middle East & Africa Follicular Lymphoma Treatment Market Size Market Share by Type (2019-2024) Table 44. Middle East & Africa Follicular Lymphoma Treatment Market Size by Application (2019-2024) & ($ Millions) Table 45. Middle East & Africa Follicular Lymphoma Treatment Market Size Market Share by Application (2019-2024) Table 46. Key Market Drivers & Growth Opportunities of Follicular Lymphoma Treatment Table 47. Key Market Challenges & Risks of Follicular Lymphoma Treatment Table 48. Key Industry Trends of Follicular Lymphoma Treatment Table 49. Global Follicular Lymphoma Treatment Market Size Forecast by Regions (2025-2030) & ($ Millions) Table 50. Global Follicular Lymphoma Treatment Market Size Market Share Forecast by Regions (2025-2030) Table 51. Global Follicular Lymphoma Treatment Market Size Forecast by Type (2025-2030) & ($ Millions) Table 52. Global Follicular Lymphoma Treatment Market Size Forecast by Application (2025-2030) & ($ Millions) Table 53. Boehringer Ingelheim GmbH Details, Company Type, Follicular Lymphoma Treatment Area Served and Its Competitors Table 54. Boehringer Ingelheim GmbH Follicular Lymphoma Treatment Product Offered Table 55. Boehringer Ingelheim GmbH Follicular Lymphoma Treatment Revenue ($ million), Gross Margin and Market Share (2019-2024) Table 56. Boehringer Ingelheim GmbH Main Business Table 57. Boehringer Ingelheim GmbH Latest Developments Table 58. Bristol-Myers Squibb Company Details, Company Type, Follicular Lymphoma Treatment Area Served and Its Competitors Table 59. Bristol-Myers Squibb Company Follicular Lymphoma Treatment Product Offered Table 60. Bristol-Myers Squibb Company Main Business Table 61. Bristol-Myers Squibb Company Follicular Lymphoma Treatment Revenue ($ million), Gross Margin and Market Share (2019-2024) Table 62. Bristol-Myers Squibb Company Latest Developments Table 63. Celgene Corporation Details, Company Type, Follicular Lymphoma Treatment Area Served and Its Competitors Table 64. Celgene Corporation Follicular Lymphoma Treatment Product Offered Table 65. Celgene Corporation Main Business Table 66. Celgene Corporation Follicular Lymphoma Treatment Revenue ($ million), Gross Margin and Market Share (2019-2024) Table 67. Celgene Corporation Latest Developments Table 68. Celldex Therapeutics, Inc. Details, Company Type, Follicular Lymphoma Treatment Area Served and Its Competitors Table 69. Celldex Therapeutics, Inc. Follicular Lymphoma Treatment Product Offered Table 70. Celldex Therapeutics, Inc. Main Business Table 71. Celldex Therapeutics, Inc. Follicular Lymphoma Treatment Revenue ($ million), Gross Margin and Market Share (2019-2024) Table 72. Celldex Therapeutics, Inc. Latest Developments Table 73. Celltrion, Inc. Details, Company Type, Follicular Lymphoma Treatment Area Served and Its Competitors Table 74. Celltrion, Inc. Follicular Lymphoma Treatment Product Offered Table 75. Celltrion, Inc. Main Business Table 76. Celltrion, Inc. Follicular Lymphoma Treatment Revenue ($ million), Gross Margin and Market Share (2019-2024) Table 77. Celltrion, Inc. Latest Developments Table 78. Cellular Biomedicine Group, Inc. Details, Company Type, Follicular Lymphoma Treatment Area Served and Its Competitors Table 79. Cellular Biomedicine Group, Inc. Follicular Lymphoma Treatment Product Offered Table 80. Cellular Biomedicine Group, Inc. Main Business Table 81. Cellular Biomedicine Group, Inc. Follicular Lymphoma Treatment Revenue ($ million), Gross Margin and Market Share (2019-2024) Table 82. Cellular Biomedicine Group, Inc. Latest Developments Table 83. Coherus BioSciences, Inc. Details, Company Type, Follicular Lymphoma Treatment Area Served and Its Competitors Table 84. Coherus BioSciences, Inc. Follicular Lymphoma Treatment Product Offered Table 85. Coherus BioSciences, Inc. Main Business Table 86. Coherus BioSciences, Inc. Follicular Lymphoma Treatment Revenue ($ million), Gross Margin and Market Share (2019-2024) Table 87. Coherus BioSciences, Inc. Latest Developments Table 88. CTI BioPharma Corp. Details, Company Type, Follicular Lymphoma Treatment Area Served and Its Competitors Table 89. CTI BioPharma Corp. Follicular Lymphoma Treatment Product Offered Table 90. CTI BioPharma Corp. Main Business Table 91. CTI BioPharma Corp. Follicular Lymphoma Treatment Revenue ($ million), Gross Margin and Market Share (2019-2024) Table 92. CTI BioPharma Corp. Latest Developments Table 93. Curis, Inc. Details, Company Type, Follicular Lymphoma Treatment Area Served and Its Competitors Table 94. Curis, Inc. Follicular Lymphoma Treatment Product Offered Table 95. Curis, Inc. Main Business Table 96. Curis, Inc. Follicular Lymphoma Treatment Revenue ($ million), Gross Margin and Market Share (2019-2024) Table 97. Curis, Inc. Latest Developments Table 98. Dynavax Technologies Corporation Details, Company Type, Follicular Lymphoma Treatment Area Served and Its Competitors Table 99. Dynavax Technologies Corporation Follicular Lymphoma Treatment Product Offered Table 100. Dynavax Technologies Corporation Main Business Table 101. Dynavax Technologies Corporation Follicular Lymphoma Treatment Revenue ($ million), Gross Margin and Market Share (2019-2024) Table 102. Dynavax Technologies Corporation Latest Developments Table 103. Eisai Details, Company Type, Follicular Lymphoma Treatment Area Served and Its Competitors Table 104. Eisai Follicular Lymphoma Treatment Product Offered Table 105. Eisai Follicular Lymphoma Treatment Revenue ($ million), Gross Margin and Market Share (2019-2024) Table 106. Eisai Main Business Table 107. Eisai Latest Developments Table 108. EpiZyme, Inc. Details, Company Type, Follicular Lymphoma Treatment Area Served and Its Competitors Table 109. EpiZyme, Inc. Follicular Lymphoma Treatment Product Offered Table 110. EpiZyme, Inc. Main Business Table 111. EpiZyme, Inc. Follicular Lymphoma Treatment Revenue ($ million), Gross Margin and Market Share (2019-2024) Table 112. EpiZyme, Inc. Latest Developments Table 113. F. Hoffmann-La Roche Ltd. Details, Company Type, Follicular Lymphoma Treatment Area Served and Its Competitors Table 114. F. Hoffmann-La Roche Ltd. Follicular Lymphoma Treatment Product Offered Table 115. F. Hoffmann-La Roche Ltd. Main Business Table 116. F. Hoffmann-La Roche Ltd. Follicular Lymphoma Treatment Revenue ($ million), Gross Margin and Market Share (2019-2024) Table 117. F. Hoffmann-La Roche Ltd. Latest Developments Table 118. Genentech, Inc. Details, Company Type, Follicular Lymphoma Treatment Area Served and Its Competitors Table 119. Genentech, Inc. Follicular Lymphoma Treatment Product Offered Table 120. Genentech, Inc. Main Business Table 121. Genentech, Inc. Follicular Lymphoma Treatment Revenue ($ million), Gross Margin and Market Share (2019-2024) Table 122. Genentech, Inc. Latest Developments Table 123. Gilead Sciences, Inc. Details, Company Type, Follicular Lymphoma Treatment Area Served and Its Competitors Table 124. Gilead Sciences, Inc. Follicular Lymphoma Treatment Product Offered Table 125. Gilead Sciences, Inc. Main Business Table 126. Gilead Sciences, Inc. Follicular Lymphoma Treatment Revenue ($ million), Gross Margin and Market Share (2019-2024) Table 127. Gilead Sciences, Inc. Latest Developments Table 128. GlaxoSmithKline Plc Details, Company Type, Follicular Lymphoma Treatment Area Served and Its Competitors Table 129. GlaxoSmithKline Plc Follicular Lymphoma Treatment Product Offered Table 130. GlaxoSmithKline Plc Main Business Table 131. GlaxoSmithKline Plc Follicular Lymphoma Treatment Revenue ($ million), Gross Margin and Market Share (2019-2024) Table 132. GlaxoSmithKline Plc Latest Developments Table 133. Hutchison MediPharma Limited Details, Company Type, Follicular Lymphoma Treatment Area Served and Its Competitors Table 134. Hutchison MediPharma Limited Follicular Lymphoma Treatment Product Offered Table 135. Hutchison MediPharma Limited Main Business Table 136. Hutchison MediPharma Limited Follicular Lymphoma Treatment Revenue ($ million), Gross Margin and Market Share (2019-2024) Table 137. Hutchison MediPharma Limited Latest Developments Table 138. Immune Design Corp. Details, Company Type, Follicular Lymphoma Treatment Area Served and Its Competitors Table 139. Immune Design Corp. Follicular Lymphoma Treatment Product Offered Table 140. Immune Design Corp. Main Business Table 141. Immune Design Corp. Follicular Lymphoma Treatment Revenue ($ million), Gross Margin and Market Share (2019-2024) Table 142. Immune Design Corp. Latest Developments Table 143. ImmunoGen, Inc. Details, Company Type, Follicular Lymphoma Treatment Area Served and Its Competitors Table 144. ImmunoGen, Inc. Follicular Lymphoma Treatment Product Offered Table 145. ImmunoGen, Inc. Main Business Table 146. ImmunoGen, Inc. Follicular Lymphoma Treatment Revenue ($ million), Gross Margin and Market Share (2019-2024) Table 147. ImmunoGen, Inc. Latest Developments List of Figures Figure 1. Follicular Lymphoma Treatment Report Years Considered Figure 2. Research Objectives Figure 3. Research Methodology Figure 4. Research Process and Data Source Figure 5. Global Follicular Lymphoma Treatment Market Size Growth Rate 2019-2030 ($ Millions) Figure 6. Follicular Lymphoma Treatment Sales by Geographic Region (2019, 2023 & 2030) & ($ millions) Figure 7. Follicular Lymphoma Treatment Sales Market Share by Country/Region (2023) Figure 8. Follicular Lymphoma Treatment Sales Market Share by Country/Region (2019, 2023 & 2030) Figure 9. Global Follicular Lymphoma Treatment Market Size Market Share by Type in 2023 Figure 10. Follicular Lymphoma Treatment in Hospital Figure 11. Global Follicular Lymphoma Treatment Market: Hospital (2019-2024) & ($ Millions) Figure 12. Follicular Lymphoma Treatment in Clinic Figure 13. Global Follicular Lymphoma Treatment Market: Clinic (2019-2024) & ($ Millions) Figure 14. Follicular Lymphoma Treatment in Others Figure 15. Global Follicular Lymphoma Treatment Market: Others (2019-2024) & ($ Millions) Figure 16. Global Follicular Lymphoma Treatment Market Size Market Share by Application in 2023 Figure 17. Global Follicular Lymphoma Treatment Revenue Market Share by Player in 2023 Figure 18. Global Follicular Lymphoma Treatment Market Size Market Share by Regions (2019-2024) Figure 19. Americas Follicular Lymphoma Treatment Market Size 2019-2024 ($ Millions) Figure 20. APAC Follicular Lymphoma Treatment Market Size 2019-2024 ($ Millions) Figure 21. Europe Follicular Lymphoma Treatment Market Size 2019-2024 ($ Millions) Figure 22. Middle East & Africa Follicular Lymphoma Treatment Market Size 2019-2024 ($ Millions) Figure 23. Americas Follicular Lymphoma Treatment Value Market Share by Country in 2023 Figure 24. United States Follicular Lymphoma Treatment Market Size Growth 2019-2024 ($ Millions) Figure 25. Canada Follicular Lymphoma Treatment Market Size Growth 2019-2024 ($ Millions) Figure 26. Mexico Follicular Lymphoma Treatment Market Size Growth 2019-2024 ($ Millions) Figure 27. Brazil Follicular Lymphoma Treatment Market Size Growth 2019-2024 ($ Millions) Figure 28. APAC Follicular Lymphoma Treatment Market Size Market Share by Region in 2023 Figure 29. APAC Follicular Lymphoma Treatment Market Size Market Share by Type in 2023 Figure 30. APAC Follicular Lymphoma Treatment Market Size Market Share by Application in 2023 Figure 31. China Follicular Lymphoma Treatment Market Size Growth 2019-2024 ($ Millions) Figure 32. Japan Follicular Lymphoma Treatment Market Size Growth 2019-2024 ($ Millions) Figure 33. Korea Follicular Lymphoma Treatment Market Size Growth 2019-2024 ($ Millions) Figure 34. Southeast Asia Follicular Lymphoma Treatment Market Size Growth 2019-2024 ($ Millions) Figure 35. India Follicular Lymphoma Treatment Market Size Growth 2019-2024 ($ Millions) Figure 36. Australia Follicular Lymphoma Treatment Market Size Growth 2019-2024 ($ Millions) Figure 37. Europe Follicular Lymphoma Treatment Market Size Market Share by Country in 2023 Figure 38. Europe Follicular Lymphoma Treatment Market Size Market Share by Type (2019-2024) Figure 39. Europe Follicular Lymphoma Treatment Market Size Market Share by Application (2019-2024) Figure 40. Germany Follicular Lymphoma Treatment Market Size Growth 2019-2024 ($ Millions) Figure 41. France Follicular Lymphoma Treatment Market Size Growth 2019-2024 ($ Millions) Figure 42. UK Follicular Lymphoma Treatment Market Size Growth 2019-2024 ($ Millions) Figure 43. Italy Follicular Lymphoma Treatment Market Size Growth 2019-2024 ($ Millions) Figure 44. Russia Follicular Lymphoma Treatment Market Size Growth 2019-2024 ($ Millions) Figure 45. Middle East & Africa Follicular Lymphoma Treatment Market Size Market Share by Region (2019-2024) Figure 46. Middle East & Africa Follicular Lymphoma Treatment Market Size Market Share by Type (2019-2024) Figure 47. Middle East & Africa Follicular Lymphoma Treatment Market Size Market Share by Application (2019-2024) Figure 48. Egypt Follicular Lymphoma Treatment Market Size Growth 2019-2024 ($ Millions) Figure 49. South Africa Follicular Lymphoma Treatment Market Size Growth 2019-2024 ($ Millions) Figure 50. Israel Follicular Lymphoma Treatment Market Size Growth 2019-2024 ($ Millions) Figure 51. Turkey Follicular Lymphoma Treatment Market Size Growth 2019-2024 ($ Millions) Figure 52. GCC Country Follicular Lymphoma Treatment Market Size Growth 2019-2024 ($ Millions) Figure 53. Americas Follicular Lymphoma Treatment Market Size 2025-2030 ($ Millions) Figure 54. APAC Follicular Lymphoma Treatment Market Size 2025-2030 ($ Millions) Figure 55. Europe Follicular Lymphoma Treatment Market Size 2025-2030 ($ Millions) Figure 56. Middle East & Africa Follicular Lymphoma Treatment Market Size 2025-2030 ($ Millions) Figure 57. United States Follicular Lymphoma Treatment Market Size 2025-2030 ($ Millions) Figure 58. Canada Follicular Lymphoma Treatment Market Size 2025-2030 ($ Millions) Figure 59. Mexico Follicular Lymphoma Treatment Market Size 2025-2030 ($ Millions) Figure 60. Brazil Follicular Lymphoma Treatment Market Size 2025-2030 ($ Millions) Figure 61. China Follicular Lymphoma Treatment Market Size 2025-2030 ($ Millions) Figure 62. Japan Follicular Lymphoma Treatment Market Size 2025-2030 ($ Millions) Figure 63. Korea Follicular Lymphoma Treatment Market Size 2025-2030 ($ Millions) Figure 64. Southeast Asia Follicular Lymphoma Treatment Market Size 2025-2030 ($ Millions) Figure 65. India Follicular Lymphoma Treatment Market Size 2025-2030 ($ Millions) Figure 66. Australia Follicular Lymphoma Treatment Market Size 2025-2030 ($ Millions) Figure 67. Germany Follicular Lymphoma Treatment Market Size 2025-2030 ($ Millions) Figure 68. France Follicular Lymphoma Treatment Market Size 2025-2030 ($ Millions) Figure 69. UK Follicular Lymphoma Treatment Market Size 2025-2030 ($ Millions) Figure 70. Italy Follicular Lymphoma Treatment Market Size 2025-2030 ($ Millions) Figure 71. Russia Follicular Lymphoma Treatment Market Size 2025-2030 ($ Millions) Figure 72. Spain Follicular Lymphoma Treatment Market Size 2025-2030 ($ Millions) Figure 73. Egypt Follicular Lymphoma Treatment Market Size 2025-2030 ($ Millions) Figure 74. South Africa Follicular Lymphoma Treatment Market Size 2025-2030 ($ Millions) Figure 75. Israel Follicular Lymphoma Treatment Market Size 2025-2030 ($ Millions) Figure 76. Turkey Follicular Lymphoma Treatment Market Size 2025-2030 ($ Millions) Figure 77. GCC Countries Follicular Lymphoma Treatment Market Size 2025-2030 ($ Millions) Figure 78. Global Follicular Lymphoma Treatment Market Size Market Share Forecast by Type (2025-2030) Figure 79. Global Follicular Lymphoma Treatment Market Size Market Share Forecast by Application (2025-2030)
